The recent launch of Donanemab Alzheimer’s therapy, marketed as Lormalzi, marks a historic milestone for Indian neurology. Specifically, this monoclonal antibody offers a disease-modifying approach for patients experiencing the earliest symptoms of cognitive decline. Unlike traditional treatments that merely mask symptoms, this therapy targets and removes amyloid-beta plaques in the brain. Consequently, it represents a significant shift from palliative care to proactive intervention.

Eli Lilly recently introduced Lormalzi in the Indian market to address the growing dementia burden. Currently, approximately 10 million Indians live with dementia, a figure that experts expect to double by 2036. Consequently, the availability of biological therapies like donanemab provides clinicians with a vital tool to potentially preserve memory for longer periods, provided they pursue advanced training in dementia care.

The Mechanism of Donanemab Alzheimer’s Therapy

Donanemab functions by specifically binding to pyroglutamate-modified amyloid-beta plaques. Once bound, it activates microglial cells to engulf and clear these abnormal protein deposits. Clinicians describe this as a “treat-to-target” approach because patients may stop the infusions once plaque levels drop sufficiently. Furthermore, clinical data suggests that this process can slow cognitive decline by up to 35% in carefully selected patients.

Clinical Protocols for Patient Selection and Monitoring

Successful implementation of this therapy requires rigorous patient screening. Specifically, the drug serves only individuals with mild cognitive impairment or mild dementia due to Alzheimer’s. Before initiation, doctors must confirm the presence of amyloid pathology via PET scans or cerebrospinal fluid analysis. Furthermore, neurologists must perform baseline MRI scans to ensure the patient does not have pre-existing microbleeds or severe vascular disease.

Safety monitoring remains paramount during the 18-month treatment course. Clinicians must conduct periodic MRI scans to monitor for Amyloid-Related Imaging Abnormalities (ARIA). This condition can involve brain edema or micro-hemorrhages. Although most ARIA cases remain asymptomatic, severe instances require immediate clinical management. Therefore, doctors should prioritize APOE genotyping to assess individual risk profiles before starting the infusions.

Challenges in the Indian Healthcare Landscape

Despite its clinical promise, several barriers to adoption exist within India. For instance, the high cost of Rs 91,688 per vial makes it inaccessible for many patients. Additionally, the limited availability of PET imaging centers and specialized monitoring infrastructure poses logistical hurdles. Nevertheless, the introduction of patient access programs and the growth of private healthcare networks may gradually bridge these gaps. Ultimately, this therapy paves the way for a more sophisticated era of neurodegenerative care in India.

Frequently Asked Questions

Q1: How do clinicians administer the drug to patients?

Clinicians administer the therapy as a monthly intravenous infusion, typically over a period of 18 months or until they confirm plaque clearance.

Q2: What are the primary side effects of this treatment?

The most significant side effects include brain swelling and microbleeds, collectively known as ARIA. Other common symptoms include headache, dizziness, and nausea.

References

Alzheimer’s Lormalzi therapy offers hope; doctors for early diagnosis, closemonitoring – ETHealthworld
Eli Lilly brings monthly Alzheimer’s therapy donanemab to India at ₹91,688 per vial – The Economic Times
Donanemab: Appropriate use recommendations – Journal of Prevention of Alzheimer’s Disease / PMC

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.